|

Suprachoroidal Administration in Subjects With Metastases to the Choroid

RECRUITINGPhase 2Sponsored by Aura Biosciences
Actively Recruiting
PhasePhase 2
SponsorAura Biosciences
Started2024-12-16
Est. completion2026-11-30
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations10 sites
View on ClinicalTrials.gov →

NCT06643884

Summary

The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary carcinoma.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.
* Have at least one Metastases to the Choroid in the study eye

Exclusion Criteria:

* Active ocular infection or disease.
* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.
* Must not be planning or expecting to switch/add systemic antineoplastic therapies during treatment

Conditions3

CancerEye CancerPrimary Cancer

Locations10 sites

Byers Eye Institute at Stanford University
Palo Alto, California, 94303
Bascom Palmer Eye Institute
Miami, Florida, 33136
Massachusetts Eye and Ear
Boston, Massachusetts, 02114
Kellogg Eye Center
Ann Arbor, Michigan, 48105
Mayo Clinic
Rochester, Minnesota, 55905

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.